Form 4: Royalty Pharma Director Henry A. Fernandez Reports Acquisition of Class A Ordinary Shares

Director Henry A. Fernandez reports the acquisition of 9,293 Class A Ordinary Shares of Royalty Pharma plc through a restricted stock unit award.

Summary

• On June 7, 2024, Henry A. Fernandez, a director of Royalty Pharma plc, acquired 9,293 Class A Ordinary Shares.
• This acquisition was due to an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The restricted stock units are generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Following the transaction, Mr. Fernandez directly owns 51,261 Class A Ordinary Shares and indirectly owns 58,200 Class A Ordinary Shares through the Fernandez 2007 Children's Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units are generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency to investors regarding the ownership changes of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it reflects a director's increased investment in the company.

Key Dates